FSIG in Virginia/D.C.

FSIG is delighted to host a Fabry Get Together in Fairfax, VA with Dr. Goker-Alpan. If you live in the area or surrounding areas and are able to attend the luncheon, please RSVP by May 15th.

Agenda

12:00 PM FSIG Welcome

12:15 PM Lunch

12:30 PM Industry Updates

1:15 PM Fabry Talk

2:15 PM Question & Answers

02:30 PM FSIG Program Updates, Thank You’s & Acknowledgements

02:30 PM Closing

Dr. Ozlem Goker-Alpan

Ozlem Goker-Alpan is the founder and president of LDRTC, a non-profit organization focusing on Lysosomal Disorders and other rare diseases. She established LDRTC in 2013 with the vision of providing quality care to individuals with rare diseases by offering clinical care and translational research under one roof.

Dr. Goker-Alpan obtained her medical degree in 1990 from Marmara University School of Medicine in Istanbul, Turkey, graduating top of her class. She completed her Pediatrics training as a Pediatric Chief Resident at SUNY Stony Brook, New York. She then pursued her first Clinical and Biochemical Genetics fellowship at the National Institutes of Health, Greater Washington Medical Genetics Program, in 1999. She served as an adjunct scientist at the National Child Health Institute. Following this, her second fellowship focused on Lysosomal Storage Disorders and Gaucher disease at the Clinical Neuroscience Branch, National Institute of Mental Health (NIMH), NIH. She also coordinated the NIH Gaucher Clinic at the Medical Genetics Branch of the National Human Genome Research Institute (NHGRI).

Dr. Goker-Alpan’s commitment to the future of healthcare in the field of Lysosomal Storage Disorders is evident in her dedication to education and training. As an established clinician and translational scientist, she is focused on providing individualized care and treatment for patients with LSDs and rare diseases. Under her leadership, LDRTC has completed multiple scientific projects exploring immune pathways and lysosomal functions to develop new diagnostic and monitoring tools in LSDs and GBA-related Parkinsonism. She also serves on the scientific advisory boards of multiple pharmaceutical companies and patient advocacy organizations.